Rationale and Design for a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction (CAPACITY HFpEF)